Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy

Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy

Since the incidence of mucosal melanoma is higher in the Japanese population compared to Caucasians, and since mucosal melanoma possesses a lower mutation burden compared to cutaneous melanoma, the efficacy of anti-PD1 antibody (Ab) monotherapy for mucosal melanoma is limited. Therefore, other targe...

Full description

Bibliographic Details
Main Authors: Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Yota Sato, Kayo Tanita, Akira Hashimoto, Setsuya Aiba
Format: Article
Language:English
Published: Karger Publishers 2020-03-01
Series:Case Reports in Oncology
Subjects:
mucosal melanoma
bone metastasis
nivolumab plus ipilimumab combination therapy
denosumab
Online Access:https://www.karger.com/Article/FullText/506327

Internet

https://www.karger.com/Article/FullText/506327

Similar Items